344 related articles for article (PubMed ID: 37237661)
1. The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions.
Piccini M; Mannelli F; Coltro G
Bioengineering (Basel); 2023 May; 10(5):. PubMed ID: 37237661
[TBL] [Abstract][Full Text] [Related]
2. Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.
Xu X; Liu R; He A; Wang F
Hematology; 2023 Dec; 28(1):2265206. PubMed ID: 37796109
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.
Wang N; He J; Liu F
Chemotherapy; 2022; 67(3):178-182. PubMed ID: 35306492
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience.
Angotzi F; Lessi F; Leoncin M; Filì C; Endri M; Lico A; Visentin A; Pravato S; Candoni A; Trentin L; Gurrieri C
Front Oncol; 2024; 14():1370405. PubMed ID: 38680863
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M
Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851
[TBL] [Abstract][Full Text] [Related]
7. Real-World Experience of Adults With Acute Myeloid Leukemia on Hypomethylating Agents With or Without Venetoclax at a Comprehensive Cancer Center.
Freeman T; Williams K; Puto M; Waller A; McLaughlin EM; Blachly JS; Roddy J
World J Oncol; 2023 Feb; 14(1):40-50. PubMed ID: 36896000
[TBL] [Abstract][Full Text] [Related]
8. Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients.
Yang TT; Song XL; Zhao YM; Ye BD; Luo Y; Xiao HW; Chen Y; Fu HR; Yu J; Liu LZ; Lai XY; Ye YS; Lan JP; Huang H; Shi JM
Ann Hematol; 2022 Dec; 101(12):2731-2741. PubMed ID: 36318288
[TBL] [Abstract][Full Text] [Related]
9. Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML.
Chen X; Zhao Y; Li Q; Fan S
Onco Targets Ther; 2023; 16():409-419. PubMed ID: 37334144
[TBL] [Abstract][Full Text] [Related]
10. Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia.
Zeng Z; Maiti A; Herbrich S; Cai T; Cavazos A; Manzella T; Ma H; Hayes K; Matthews J; DiNardo CD; Daver NG; Konopleva MY
Cancer; 2023 Feb; 129(4):531-540. PubMed ID: 36477735
[TBL] [Abstract][Full Text] [Related]
11. A retrospective comparison of salvage intensive chemotherapy
Park S; Kwag D; Kim TY; Lee JH; Lee JY; Min GJ; Park SS; Yahng SA; Jeon YW; Shin SH; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim HJ
Ther Adv Hematol; 2022; 13():20406207221081637. PubMed ID: 35340720
[TBL] [Abstract][Full Text] [Related]
12. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.
Weng G; Zhang Y; Yu G; Luo T; Yu S; Xu N; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Shao R; Du X; Jin H; Liu Q
J Intern Med; 2023 Mar; 293(3):329-339. PubMed ID: 36284445
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
Brancati S; Gozzo L; Romano GL; Vetro C; Dulcamare I; Maugeri C; Parisi M; Longo L; Vitale DC; Di Raimondo F; Drago F
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008186
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?
Rahmé R; Braun T
J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256681
[No Abstract] [Full Text] [Related]
16. Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia.
Sandhu KS; Dadwal S; Yang D; Mei M; Palmer J; Salhotra A; Al Malki M; Aribi A; Ali H; Khaled S; Forman SJ; Snyder D; Nakamura R; Stein AS; Marcucci G; Aldoss I; Pullarkat V
Biol Blood Marrow Transplant; 2020 Dec; 26(12):e322-e327. PubMed ID: 32866594
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
Graveno ME; Carulli A; Freyer CW; Mangan BL; Nietupski R; Loren AW; Frey NV; Porter DL; Gill SI; Hexner EO; Luger SM; Martin ME; McCurdy SR; Perl AE; Babushok DV; Pratz KW
Leuk Lymphoma; 2022 Jul; 63(7):1645-1650. PubMed ID: 35259056
[TBL] [Abstract][Full Text] [Related]
18. Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia.
Sciumè M; Bosi A; Canzi M; Ceparano G; Serpenti F; De Roberto P; Fabris S; Tagliaferri E; Cavallaro F; Onida F; Fracchiolla NS
Front Oncol; 2023; 13():1149298. PubMed ID: 37051529
[TBL] [Abstract][Full Text] [Related]
19. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Todisco E; Papayannidis C; Fracchiolla N; Petracci E; Zingaretti C; Vetro C; Martelli MP; Zappasodi P; Di Renzo N; Gallo S; Audisio E; Griguolo D; Cerchione C; Selleri C; Mattei D; Bernardi M; Fumagalli M; Rizzuto G; Facchini L; Basilico CM; Manfra I; Borlenghi E; Cairoli R; Salutari P; Gottardi M; Molteni A; Martini V; Lunghi M; Fianchi L; Cilloni D; Lanza F; Abruzzese E; Cascavilla N; Rivellini F; Ferrara F; Maurillo L; Nanni J; Romano A; Cardinali V; Gigli F; Roncoroni E; Federico V; Marconi G; Volpi R; Sciumè M; Tarella C; Rossi G; Martinelli G;
Cancer; 2023 Apr; 129(7):992-1004. PubMed ID: 36692409
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting.
Gong X; Zhang Y; He X; Moloudizargari M; Yu T; Wang L; Liu W; Jin L; Xu H; Xu Y; Tao Z; Qian W
Exp Hematol Oncol; 2023 Jun; 12(1):57. PubMed ID: 37391809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
